FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced presentations of data from its IMerge Phase 3 clinical trial ...
More than 80 percent of deaths in the operating room and 50 percent of deaths in the first 24 hours after injury are due to massive blood loss and impaired coagulation. While only 3 percent of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback